Table 1 Demographics of PNH patients at baseline

Age

47.13

15.25

46.13

14.97

0.68

0.50

0.001

Years Since Diagnosis

8.72

8.28

9.39

9.05

-0.77

0.44

0.001

Baseline BMI

23.72

3.86

25.93

4.64

-5.14

 < .0005

0.059

No.

%

No.

%

Female

71

42%

138

51%

3.86

0.05

0.009

Region

Europe

5

3%

214

79%

346.74

 < .0005

0.787

Japan

47

27%

0

0%

Latin America

1

1%

21

8%

North America

9

5%

24

9%

Rest of Asia Pacific

109

64%

11

4%

Other variables included in propensity score

Trial

43.75

 < .0005

0.099

301

129

75%

117

43%

302

42

25%

153

57%

Observed LDH category

 44.23

< .0005

0.100 

LDH < 1.5xULN

42

25%

153

57%

LDH 1.5—< 3xULN

16

9%

18

7%

LDH >  = 3xULN

113

66%

99

37%

Observed pRBC stratum

49.22

< .0005

 0.112

Not measured

42

25%

153

57%

0 unit pRBC

24

14%

19

7%

1–14 units pRBC

74

43%

82

30%

 > 14 units pRBC

31

18%

16

6%

Immuno-suppressant treatment

57

33%

167

62%

 34.07

 .0005

 0.077

Aplastic anemia

60

35%

92

34%

0.05

0.83

 < .001

Myelodysplastic syndrome

8

5%

14

5%

0.06

 0.81

 < .001

Bone marrow disorder

66

39%

100

37%

0.11

 0.74

 < .001